Long-term Study Of Paroxetine in Women and Men
Phase 3
Completed
- Conditions
- Social Phobia
- Registration Number
- NCT00264654
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change from baseline in the LSAS total score at week 52 (Score at week 52- Score at week 0) 52 Weeks
- Secondary Outcome Measures
Name Time Method Proportion of patients responding with a CGI Global Improvement Item. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment. 52 Weeks
Trial Locations
- Locations (1)
GSK Investigational Site